Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352782 | PMC |
| http://dx.doi.org/10.3346/jkms.2021.36.e226 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Young TPI: empowering animal-free science among the next- generation of scientists.
Front Toxicol
January 2025
Founding Board Member of Young TPI, The Hague, Netherlands.
Strategies emphasizing animal-free innovation are imperative for the contemporary and future scientific research. They not only address important ethical concerns, but also should directly improve research accuracy and reliability through redirecting scientific inquiry toward more reliable and translatable methodologies. Promotion and encouragement for use of animal-free innovations among the next-generation of scientists, alongside knowledge acquisition and training in the increased capabilities of novel technologies, are fundamental for advancing science and the welfare of animals used for scientific purposes.
View Article and Find Full Text PDFSimultaneous Unbinned Differential Cross-Section Measurement of Twenty-Four Z+jets Kinematic Observables with the ATLAS Detector.
Phys Rev Lett
December 2024
CERN, Geneva, Switzerland.
Z boson events at the Large Hadron Collider can be selected with high purity and are sensitive to a diverse range of QCD phenomena. As a result, these events are often used to probe the nature of the strong force, improve Monte Carlo event generators, and search for deviations from standard model predictions. All previous measurements of Z boson production characterize the event properties using a small number of observables and present the results as differential cross sections in predetermined bins.
View Article and Find Full Text PDFResponsible Use of Population Neuroscience Data in the ABCD: Towards Standards of Accountability and Integrity.
Eur J Neurosci
January 2025
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, California, USA.
This editorial focuses on the issue of data misuse that is increasingly evidenced in social media as well as some premiere scientific journals. This issue is of critical importance to open science projects in general, and ABCD in particular, given the broad array of biological, behavioural and environmental information collected on this American sample of 12,000 youth and parents. ABCD data are already widely used with over 1,200 publications and twice as many citations per year as expected (relative citation index based on year, field and journal).
View Article and Find Full Text PDFUltrafast dynamic contrast-enhanced breast MRI with quantitative perfusion parameters in differentiating breast cancer: a study focusing on triple-negative and HER2 positive breast cancer.
Front Oncol
January 2025
Department of Radiology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background: In the realm of breast cancer diagnosis and treatment, accurately discerning molecular subtypes is of paramount importance, especially when aiming to avoid invasive tests. The updated guidelines for diagnosing and treating HER2 positive advanced breast cancer, as presented at the 2021 National Breast Cancer Conference and the Annual Meeting of the Chinese Society of Clinical Oncology, highlight the significance of this approach. A new generation of drug-antibody combinations has emerged, expanding the array of treatment options for HER2 positive advanced breast cancer and significantly improving patient survival rates.
View Article and Find Full Text PDFA Review of Real-World Experience With Ruxolitinib for Myelofibrosis.
Clin Lymphoma Myeloma Leuk
December 2024
Incyte Corporation, Wilmington, DE.
Myelofibrosis (MF) is a rare myeloproliferative neoplasm characterized by progressive bone marrow fibrosis and splenomegaly. Ruxolitinib is the standard-of-care first-line treatment option for MF. This review summarizes real-world effectiveness and safety of ruxolitinib in more than 4500 patients with MF from real-world settings, including expanded-access and phase 4 trials, as well as registry, postmarketing, and retrospective studies in the 10 years since regulatory approval.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!